- Home
- BLNK vs CCCC Comparison
BLNK vs CCCC Comparison
Compare BLNK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- CCCC
- Stock Information
- Founded
- BLNK 2009
- CCCC 2015
- Country
- BLNK United States
- CCCC United States
- Employees
- BLNK N/A
- CCCC N/A
- Industry
- BLNK Industrial Specialties
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- CCCC Health Care
- Exchange
- BLNK Nasdaq
- CCCC Nasdaq
- Market Cap
- BLNK 295.1M
- CCCC 405.6M
- IPO Year
- BLNK N/A
- CCCC 2020
- Fundamental
- Price
- BLNK $2.11
- CCCC $6.25
- Analyst Decision
- BLNK Strong Buy
- CCCC Buy
- Analyst Count
- BLNK 7
- CCCC 6
- Target Price
- BLNK $5.79
- CCCC $10.50
- AVG Volume (30 Days)
- BLNK 4.4M
- CCCC 731.1K
- Earning Date
- BLNK 11-07-2024
- CCCC 10-30-2024
- Dividend Yield
- BLNK N/A
- CCCC N/A
- EPS Growth
- BLNK N/A
- CCCC N/A
- EPS
- BLNK N/A
- CCCC N/A
- Revenue
- BLNK $156,918,000.00
- CCCC $29,378,000.00
- Revenue This Year
- BLNK $6.96
- CCCC $39.70
- Revenue Next Year
- BLNK $31.64
- CCCC N/A
- P/E Ratio
- BLNK N/A
- CCCC N/A
- Revenue Growth
- BLNK 66.29
- CCCC 83.26
- 52 Week Low
- BLNK $1.53
- CCCC $1.06
- 52 Week High
- BLNK $4.66
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- BLNK 62.35
- CCCC 54.57
- Support Level
- BLNK $1.63
- CCCC $6.26
- Resistance Level
- BLNK $2.14
- CCCC $7.14
- Average True Range (ATR)
- BLNK 0.12
- CCCC 0.37
- MACD
- BLNK 0.04
- CCCC 0.12
- Stochastic Oscillator
- BLNK 94.12
- CCCC 58.99
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.